iShares MBS ETF (MBB) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- -Sector
- $96.9152W High
- $92.4152W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track iShares MBS ETF (MBB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, iShares MBS ETF has traded between a low of $92.39 and a high of $96.91, highlighting its annual price range. Buy and sell iShares MBS ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Most Recent News
Tectonic Therapeutic advances TX45 trial with strong data and solid cash runway through 2029, reducing financing risks.
Tectonic Therapeutic has shown promising Phase 1b data for its TX45 drug targeting pulmonary hypertension in heart failure patients, supported by external Merck trial results. The company’s financial position is strong, with cash to fund operations t...

US federal debt tops $40T as massive AI data center investments boost economy and tech growth.
US federal debt has surpassed $40 trillion, driven by significant government and corporate borrowing to fund a large-scale AI data center infrastructure expansion. Despite high debt levels, the economy remains strong with a 4.1% unemployment rate in ...

Dogwood Therapeutics advances Halneuron for chemo-induced neuropathic pain, plans trial for SP16 adjunct therapy.
Dogwood Therapeutics, a clinical-stage biotech company, highlighted progress on Halneuron, a NaV1.7 inhibitor aimed at treating chemotherapy-induced neuropathic pain. The company also announced plans to start clinical trials for SP16, an LRP1 agonist...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.